# Replication of the LEADER Diabetes Trial in Healthcare Claims

> **NCT03936049** · — · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 168690 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** DPP-4 inhibitor

## Key facts

- **NCT ID:** NCT03936049
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-22
- **Primary completion:** 2021-02-18
- **Final completion:** 2021-02-18
- **Target enrollment:** 168690 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03936049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03936049, "Replication of the LEADER Diabetes Trial in Healthcare Claims". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03936049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*